Gilead Sciences

History

2025: Agreement to pay $202 million for kickbacks to doctors

On April 29, 2025, the US Department of Justice announced that Gilead Sciences had reached an amicable agreement with the US authorities in proceedings related to the provision of kickbacks to doctors for prescribing HIV drugs. Gilead will pay a total of more than $200 million to settle the fraud lawsuit.

According to the investigation, to increase sales of its own drugs, such as Stribild, Genvoya, Complera, Odefsey, Descovy and Biktarvy, Gilead held events in the HIV Speaker Programs series. They were attended by attracted medical staff specializing in the treatment of HIV. The events were supposed to be educational in nature with modest dinners. Instead, Gilead was said to have paid speaker fees, paid for luxury meals at expensive restaurants and covered travel costs, including to "preferred" locations such as Hawaii Miami and New Orleans. In addition, some specialists attended events on the same topic several times, although they had minimal educational value for them.

𝓲

Фото: dailybreeze.com

Many medical staff who received kickbacks then prescribed Gilead's HIV drugs to their patients. As a result, federal health programs have paid out millions of dollars in refunds on such prescriptions. According to the investigation, from January 2011 to November 2017, Gilead spent tens of millions of dollars on programs to promote its drugs, including more than $20 million in performance fees.

Under the terms of the settlement agreement, Gilead will pay a total of $202 million, of which almost $177 million will go to the US government, and the remaining part (about $25 million) will be distributed among various American states.^[1]

2022

Gilead bought a developer of drugs to restore the immune balance for $405 million

MiroBio is a private clinical-stage biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint antibody agonists, to restore immune balance in patients with autoimmune diseases. Read more here

Payment of $1.25 billion to GlaxoSmithKline for theft of developments for HIV drug

On February 2, 2022, it became known that the British company GlaxoSmithKline (GSK) will receive $1.25 billion from Gilead Sciences as part of a settlement between its drug development unit HIV ViiV Healthcare and GSK.

The settlement announced by GSK concerns the antiretroviral drug Gilead Biktarvy, a drug used to test for viruses that cause AIDS, which GSK said in 2018 violated the rights to dolutegravir and other similar compounds of its ViiV Healthcare unit.

GSK sued Gilead $1.25 billion for stealing developments for HIV drug

In accordance with the agreement, Gilead will pay $1.25 billion to GSK ViiV Healthcare in the first quarter of 2022. In addition, the company will pay 3% royalties on U.S. sales of the widely marketed HIV drug Biktarvy before the GSK patent expires in October 2027.

GSK, Pfizer and Shionogi, each holding a stake in ViiV, will receive a portion of the income from payments and royalties in proportion to their shares.

In a message to clients, Jefferies analyst Peter Welford said the deal provides "welcome growth potential" for GSK as it prepares to partition the consumer healthcare sector. The analyst cited "rough" math to suggest that Biktarvy will generate about $50 billion in the United States from February 2022 to October 2027. This means that the licensed part of the transaction at the time of settlement is about £1.45 billion ($1.97 billion), the analyst wrote.

In the patent dispute, ViiV Healthcare and its shareholders GSK and Shionogi said Gilead's Biktarvy violated their dolutegravir-related patents. Gilead is a combination of bictegravir, tenofovir alafenamide, and emtricitabine.

Through the settlement, Gilead will receive a global license for certain patents related to the ViiV drug. ViiV and its shareholders agreed not to apply the patents "in connection with any past or future infringement claims relating to Biktarvy" or any products containing biktegravir.^[2]

Cancer drug recall due to deadly side effects

On January 14, 2022, the American biopharmaceutical company Gilead Sciences notified the regulator health care USA of its decision to voluntarily abandon the use of its drug Zydelig for the treatment of two types, namely cancer follicular lymphoma and small lymphocytic. leukemias More. here

2020

Purchase of German biotech firm MYR Pharmaceuticals

In early December 2020, Gilead Sciences announced the acquisition of the German biotechnology firm MYR Pharmaceuticals for €1.15 billion with a possible surcharge of up to €300 million. The deal ensured the rapid growth of Gilead Sciences shares amid the registration of the drug remdesivir for the treatment of COVID-19. Read more here.

Buying Immunomedics

On September 14, 2020, Gilead announced the purchase of Immunomedics for $21 billion. The value of the transaction in terms of one share of the sold company is $88, which is 108% more than the rate of quotations by the closing of the exchange on September 11. Read more here.